Boswellia Serrata (Indian Frankincense) and Brain Cancer (Glioblastoma): Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Boswellia Serrata (Indian Frankincense) and Brain Cancer (Glioblastoma): Latest Research 2026

This page summarizes the current state of scientific research on Boswellia Serrata (Indian Frankincense) in the context of Brain Cancer (Glioblastoma) as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your neuro-oncologist for personalized guidance.

Compound Overview

Boswellia Serrata (Indian Frankincense) (Herbal / Anti-inflammatory) — Dietary supplement; not FDA-approved

Mechanism of action: Inhibits 5-lipoxygenase (5-LOX); reduces pro-inflammatory leukotrienes; anti-inflammatory BAs; inhibits NF-κB

Current evidence level: RCT evidence for osteoarthritis; Phase II for brain edema reduction; Cochrane review for IBD

2026 Research Landscape

Research has directly examined Boswellia Serrata (Indian Frankincense) in Brain Cancer, making this a field with active scientific interest.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Boswellia Serrata (Indian Frankincense) affects the biological pathways involved in Brain Cancer (Glioblastoma) progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Clinical trials: Phase I/II investigations examining Boswellia Serrata (Indian Frankincense) in Brain Cancer patients are ongoing or recently completed

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Boswellia Serrata (Indian Frankincense)[tiab]) AND (Brain Cancer (Glioblastoma)[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Boswellia Serrata (Indian Frankincense) keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Boswellia Serrata (Indian Frankincense) + Brain Cancer research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in Brain Cancer patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Boswellia Serrata (Indian Frankincense) for Brain Cancer?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Boswellia Serrata (Indian Frankincense) Brain Cancer (Glioblastoma)' filtered to the last 2 years. The current evidence level is: RCT evidence for osteoarthritis; Phase II for brain edema reduction; Cochrane review for IBD.

Are there any 2025-2026 clinical trials for Boswellia Serrata (Indian Frankincense) in Brain Cancer?

Check ClinicalTrials.gov with 'Boswellia Serrata (Indian Frankincense)' as intervention and 'Brain Cancer (Glioblastoma)' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your neuro-oncologist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Boswellia Serrata (Indian Frankincense) in Brain Cancer changed recently?

The field evolves rapidly. The current evidence classification is: RCT evidence for osteoarthritis; Phase II for brain edema reduction; Cochrane review for IBD. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.